Skip to main content
. 2019 Nov 28;10:5428. doi: 10.1038/s41467-019-13315-x

Fig. 3.

Fig. 3

PIM1 inhibition lacks potency but enhances the efficacy of ALK inhibitors. a RT-qPCR-based expression levels of PIM1 in 25 neuroblastoma cell lines, normalized to GIMEN cell line expression levels. Data represent means ± s.d. of technical triplicates. b 14-day colony formation assay of ALK-positive NB cell lines treated with the indicated doses of AZD1208. c 72-h dose–response assays of ALK-positive NB cell lines treated with AZD1208 or PIMi. Data represent means ± s.d. of technical triplicates. d, e Analysis of PIM1 levels by RT-qPCR in d CHLA-20 or e KELLY cells with shRNA-mediated knockdown of PIM1. NT, non-targeting. Data represent means ± s.d. of triplicate experiments. f, g 72-h dose–response assays following brigatinib or ceritinib exposure in f CHLA-20 cells or g KELLY cells treated with PIM1-targeting or NT shRNA. Data points represent means ± s.d. of duplicate f or triplicate g experiments. ED50 values were compared by an unpaired Student’s t-test. Source data for 3a and 3d-g are provided as a Source Data file.